ArticleJournal of hematology & oncology2020
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
Article in Journal of hematology & oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Post-transplant cyclophosphamideFrontiers in oncology · 2023Pooled it
- Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.International journal of hematology · 2022Pooled it
- GvHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan-Haematologica · 2026Trial
- Comparison of haploidentical, matched sibling and matched unrelated donor allo-HCT in adult patients with AML in complete remission with measurable residual disease: a study from the Global committee and the ALWP of the EBMT.Experimental hematology & oncology · 2026Article
- Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT.Bone marrow transplantation · 2026Article
- PTCy-based GVHD prophylaxis helps navigate donor selection in secondary AML undergoing alternative donor transplantation.Bone marrow transplantation · 2026Article
- Outcomes After Matched Sibling Donor Versus Haploidentical Hematopoietic Stem Cell Transplantation With Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis.Transplantation and cellular therapy · 2026Article
- PTCy-based allo-BMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.Blood advances · 2026Article
- Donor selection for allogeneic hematopoietic cell transplantation in the posttransplant cyclophosphamide era.International journal of hematology · 2026Review
- Late outcomes after posttransplant cyclophosphamide-based GVHD prophylaxis in patients with AML: an ALWP-EBMT study.Blood neoplasia · 2026Article
- HLA-matched versus haploidentical donor transplantation with post-transplant cyclophosphamide: a study on behalf of the donor/source working group of the Japanese society for transplantation and cellular therapy.Annals of hematology · 2026Article
- Article
- Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party.Bone marrow transplantation · 2026Article
- Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.Blood advances · 2026Article
- Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity.Bone marrow transplantation · 2026Article
- Article
- Allogeneic transplantation in adverse-risk acute myeloid leukemia: Challenges, strategies, and future directions.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia.Blood advances · 2025Article
- Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia: a study of the SAAWP EBMT.Bone marrow transplantation · 2025Article
- Cytokine release syndrome: implications for transplant outcomes in haploidentical and HLA-matched HSCT using PTCy.Bone marrow transplantation · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 12 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched sibling (MSD) and matched unrelated (MUD) transplants. There is no information on the impact of donor types using homogeneous prophylaxis with PTCy.
methodsWe retrospectively compared outcomes of adult patients with acute myeloid leukemia (AML) in first complete remission (CR1) who received a first allogeneic stem cell transplantation (SCT) with PTCy as GVHD prophylaxis from MSD (n = 215), MUD (n = 235), and Haplo (n = 789) donors registered in the EBMT database between 2010 and 2017.
resultsThe median follow-up was 2 years. Haplo-SCT carried a significantly increased risk of acute grade II-IV GVHD (HR 1.6; 95% CI 1.1-2.4) and NRM (HR 2.6; 95% CI 1.5-4.5) but a lower risk of relapse (HR 0.7; 95% CI 0.5-0.9) that translated to no differences in LFS (HR 1.1; 95% CI 0.8-1.4) or GVHD/relapse-free survival (HR 1; 95% CI 0.8-1.3). Interestingly, the use of peripheral blood was associated with an increased risk of acute (HR 1.9; 95% CI 1.4-2.6) and chronic GVHD (HR 1.7; 95% CI 1.2-2.4) but a lower risk of relapse (HR 0.7; 95% CI 0.5-0.9).
conclusionsThe use of PTCy in patients with AML in CR1 receiving SCT from MSD, MUD, and Haplo is safe and effective. Haplo-SCT had increased risk of acute GVHD and NRM and lower relapse incidence but no significant difference in survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.